AtTEnd, 2023 NCT03603184
atezolizumab plus SoC (n=360) vs. placebo plus SoC (n=189)
randomized controlled trial
atezolizumab
paclitaxel 175 mg/m2 carboplatin every 21 days for 6-8 cycles or PD. Atezolizumab IV1200 mg, every 21 days progression
placebo
paclitaxel 175 mg/m2 carboplatin every 21 days for 6-8 cycles or PD placebo IV every 21 days
Paclitaxel and Carboplatin
endometrial cancer
double-blind
89 sites across 10 countries
result from esmo congress 2023. no protocol available, no information about multiplicity control strategy and interim analysis management